Logo do repositório
 
Publicação

Open-label placebo treatment in chronic low back pain: A randomized controlled trial

2016-12Artigo científico Acesso aberto
Ver registo simples
datacite.subject.fosCiências Sociais::Psicologia
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorCarvalho, Cláudia
dc.contributor.authorCaetano, Joaquim Machado
dc.contributor.authorCunha, Lidia
dc.contributor.authorRebouta, Paula
dc.contributor.authorKaptchuk, Ted J.
dc.contributor.authorKirsch, Irving
dc.date.accessioned2026-07-01T14:12:01Z
dc.date.available2026-07-01T14:12:01Z
dc.date.issued2016-12
dc.description.abstractAbstract: This randomized controlled trial was performed to investigate whether placebo effects in chronic low back pain could be harnessed ethically by adding open-label placebo (OLP) treatment to treatment as usual (TAU) for 3 weeks. Pain severity was assessed on three 0- to 10-point Numeric Rating Scales, scoring maximum pain, minimum pain, and usual pain, and a composite, primary outcome, total pain score. Our other primary outcome was back-related dysfunction, assessed on the Roland–Morris Disability Questionnaire. In an exploratory follow-up, participants on TAU received placebo pills for 3 additional weeks. We randomized 97 adults reporting persistent low back pain for more than 3 months' duration and diagnosed by a board-certified pain specialist. Eighty-three adults completed the trial. Compared to TAU, OLP elicited greater pain reduction on each of the three 0- to 10-point Numeric Rating Scales and on the 0- to 10-point composite pain scale, with moderate to large effect sizes. Pain reduction on the composite Numeric Rating Scales was 1.5 (95% confidence interval: 1.0-2.0) in the OLP group and 0.2 (−0.3 to 0.8) in the TAU group. Open-label placebo treatment also reduced disability compared to TAU, with a large effect size. Improvement in disability scores was 2.9 (1.7-4.0) in the OLP group and 0.0 (−1.1 to 1.2) in the TAU group. After being switched to OLP, the TAU group showed significant reductions in both pain (1.5, 0.8-2.3) and disability (3.4, 2.2-4.5). Our findings suggest that OLP pills presented in a positive context may be helpful in chronic low back pain.eng
dc.identifier.citation• Carvalho, C., Pais, M., Cunha, L., Rebouta, P., Kaptchuk, T. J., & Kirsch, I. (2021). Open-label placebo for chronic low back pain: a 5-year follow-up. Pain, 162(5), 1521-1527. https://doi.org/10.1097/j.pain.0000000000000700
dc.identifier.doi10.1097/j.pain.0000000000000700
dc.identifier.issn0304-3959
dc.identifier.issn1872-6623
dc.identifier.urihttp://hdl.handle.net/10400.12/14013
dc.language.isoeng
dc.peerreviewedyes
dc.publisherOvid Technologies (Wolters Kluwer Health)
dc.relation.ispartofPain
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleOpen-label placebo treatment in chronic low back pain: A randomized controlled trialeng
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage1527
oaire.citation.issue12
oaire.citation.startPage1521
oaire.citation.titlePain
oaire.citation.volume157
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
open_label_placebo_treatment_in_chronic_low_back.17 (1).pdf
Tamanho:
371.74 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
4.03 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

APPsyCI - Artigos em revistas científicas internacionais